CN101501025A - 用于治疗疼痛、阿尔茨海默病和精神分裂症的毒蕈碱性受体激动剂 - Google Patents

用于治疗疼痛、阿尔茨海默病和精神分裂症的毒蕈碱性受体激动剂 Download PDF

Info

Publication number
CN101501025A
CN101501025A CNA2007800295059A CN200780029505A CN101501025A CN 101501025 A CN101501025 A CN 101501025A CN A2007800295059 A CNA2007800295059 A CN A2007800295059A CN 200780029505 A CN200780029505 A CN 200780029505A CN 101501025 A CN101501025 A CN 101501025A
Authority
CN
China
Prior art keywords
alkyl
alkoxy
piperidinyl
cycloalkyl
benzimidazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800295059A
Other languages
English (en)
Chinese (zh)
Inventor
程云兴
梅尔纳兹·波拉什拉夫
米罗斯劳·托马斯泽夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN101501025A publication Critical patent/CN101501025A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CNA2007800295059A 2006-06-09 2007-06-08 用于治疗疼痛、阿尔茨海默病和精神分裂症的毒蕈碱性受体激动剂 Pending CN101501025A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81220906P 2006-06-09 2006-06-09
US60/812,209 2006-06-09

Publications (1)

Publication Number Publication Date
CN101501025A true CN101501025A (zh) 2009-08-05

Family

ID=38801727

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800295059A Pending CN101501025A (zh) 2006-06-09 2007-06-08 用于治疗疼痛、阿尔茨海默病和精神分裂症的毒蕈碱性受体激动剂

Country Status (18)

Country Link
US (1) US7956069B2 (https=)
EP (1) EP2035411A1 (https=)
JP (1) JP2009539831A (https=)
KR (1) KR20090018210A (https=)
CN (1) CN101501025A (https=)
AR (1) AR061305A1 (https=)
AU (1) AU2007256012A1 (https=)
BR (1) BRPI0712331A2 (https=)
CA (1) CA2654138A1 (https=)
EC (1) ECSP088966A (https=)
IL (1) IL195431A0 (https=)
MX (1) MX2008015136A (https=)
NO (1) NO20085270L (https=)
RU (1) RU2008147542A (https=)
SA (1) SA07280303B1 (https=)
TW (1) TW200813018A (https=)
UY (1) UY30397A1 (https=)
WO (1) WO2007142583A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068798A (zh) * 2010-09-03 2013-04-24 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的二-氮杂环丁烷二酰胺
CN112533905A (zh) * 2018-04-06 2021-03-19 塔罗制药公司 可用于治疗疼痛和炎症的茚衍生物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815405A (en) * 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) * 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) * 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) * 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300
GB0817982D0 (en) * 2008-10-01 2008-11-05 Glaxo Group Ltd Compounds
EP2398320A4 (en) * 2009-02-19 2012-09-19 Univ Vanderbilt ALLOSTERIC ANTAGONISTS OF AMIDOBIPIPERIDINECARBOXYLATE M1, ANALOGUES AND DERIVATIVES THEREOF, AND METHODS FOR THEIR MANUFACTURE AND USE
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3066434D1 (en) 1979-11-21 1984-03-08 Kyowa Hakko Kogyo Kk Novel piperidine derivatives, method for the preparation thereof and pharmaceutical compositions containing them
DE4302051A1 (de) 1993-01-26 1994-07-28 Thomae Gmbh Dr K 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
JP2002515008A (ja) * 1994-10-27 2002-05-21 メルク エンド カンパニー インコーポレーテッド ムスカリン・アンタゴニスト
US5756508A (en) * 1995-10-31 1998-05-26 Merck & Co., Inc. Muscarine antagonists
WO1997016192A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH10158192A (ja) 1996-10-03 1998-06-16 Eisai Co Ltd 移植片対宿主疾患（ｇｖｈｄ）の治療および臓器移植時の移植片拒絶反応抑制のための医薬組成物
SE9704546D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
AU2307999A (en) * 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
JP2000323278A (ja) 1999-05-14 2000-11-24 Toray Ind Inc 発光素子
ATE275141T1 (de) 1999-10-13 2004-09-15 Banyu Pharma Co Ltd Substituierte imidazolin-derivate
SE9904652D0 (sv) 1999-12-17 1999-12-17 Astra Pharma Prod Novel Compounds
EP1309593B1 (en) 2000-08-14 2006-03-15 Ortho-McNeil Pharmaceutical, Inc. Substituted pyrazoles
JP2002302675A (ja) 2001-04-06 2002-10-18 Fuji Photo Film Co Ltd 液晶組成物、それを用いた液晶素子およびアゾ化合物
US6872733B2 (en) * 2001-04-18 2005-03-29 Euro-Celtique S.A. Benzimidazolone compounds
NZ551453A (en) 2001-04-18 2008-02-29 Euro Celtique Sa Nociceptin analogs for the treatment of pain
JPWO2002085890A1 (ja) * 2001-04-20 2004-08-12 萬有製薬株式会社 ベンズイミダゾロン誘導体
ATE516030T1 (de) * 2001-10-02 2011-07-15 Acadia Pharm Inc Benzimidazolidinon-derivate als muscarinische mittel
WO2004089942A2 (en) * 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
PT1499316E (pt) 2002-04-18 2008-06-30 Schering Corp Derivados de (1-4-piperidinil)benzimidazole úteis como antagonistas de histamina h3
JP2005532361A (ja) * 2002-06-17 2005-10-27 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症の治療用の眼科用組成物
WO2004069828A1 (ja) * 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation ピペリジン化合物およびその医薬用途
CA2524221A1 (en) 2003-04-30 2004-11-18 The Institutes For Pharmaceutical Discovery, Llc Substituted heteroaryls as inhibitors of protein tyrosine phosphatases
US20050250794A1 (en) 2003-12-19 2005-11-10 Andrew Napper Methods of treating a disorder
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
AU2005249494A1 (en) * 2004-05-28 2005-12-15 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EP1790637B1 (en) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Derivatives of N-4-piperidyl urea and medicaments containing them as active ingredient
CA2581930A1 (en) 2004-09-27 2006-04-06 Jane Trepel Modulating mxa expression
WO2006038594A1 (ja) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
TW200815351A (en) 2006-05-02 2008-04-01 Astrazeneca Ab Novel compounds
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (es) 2008-02-28 2009-09-30 "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación"
US20090221642A1 (en) 2008-03-03 2009-09-03 Astrazeneca Ab Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176
US20090275574A1 (en) 2008-05-05 2009-11-05 Astrazeneca Ab Novel compounds-300

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103068798A (zh) * 2010-09-03 2013-04-24 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的二-氮杂环丁烷二酰胺
CN112533905A (zh) * 2018-04-06 2021-03-19 塔罗制药公司 可用于治疗疼痛和炎症的茚衍生物

Also Published As

Publication number Publication date
IL195431A0 (en) 2009-08-03
JP2009539831A (ja) 2009-11-19
SA07280303B1 (ar) 2011-02-23
KR20090018210A (ko) 2009-02-19
AU2007256012A1 (en) 2007-12-13
WO2007142583A1 (en) 2007-12-13
TW200813018A (en) 2008-03-16
NO20085270L (no) 2009-01-07
ECSP088966A (es) 2009-01-30
CA2654138A1 (en) 2007-12-13
US20070287695A1 (en) 2007-12-13
UY30397A1 (es) 2008-01-31
EP2035411A1 (en) 2009-03-18
MX2008015136A (es) 2008-12-10
RU2008147542A (ru) 2010-07-20
BRPI0712331A2 (pt) 2012-04-03
US7956069B2 (en) 2011-06-07
AR061305A1 (es) 2008-08-20

Similar Documents

Publication Publication Date Title
CN101501025A (zh) 用于治疗疼痛、阿尔茨海默病和精神分裂症的毒蕈碱性受体激动剂
CN101874020B (zh) 作为毒蕈碱受体激动剂的哌啶衍生物
AU2007256014B2 (en) Muscarinic receptor agonists that are effective in the treatment of pain, Alzheimer's disease and schizophrenia
CN102015687A (zh) 毒蕈碱性受体激动剂、其组合物、其治疗方法以及其制备方法177
CN101472917A (zh) 作为大麻素1（cb1）受体配体的苯并咪唑5-磺酰胺衍生物
US20090275574A1 (en) Novel compounds-300
US20100173941A1 (en) Muscarinic Receptor Agonists that are Effective in the Treatment of Pain, Alzheimer's Disease and Schizophrenia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090805